Details werden geladen...
REGENXBIO bets on FDA flexibility with filing plans for Duchenne gene therapy - BioSpace
A few short days after announcing an FDA pivot on a separate asset, REGENXBIO is planning to test the agency’s apparent newfound rare disease outlook on another late-stage gene therapy.
Ähnliche Seiten
UniQure plans Q3 submission for Huntington’s gene therapy after FDA reverses course—again - BioSpace
https://www.biospace.com/fda/uniqure-plans-q3-submission-for-huntingtons-gene-therapy-after-fda-reverses-course-again
Wagering on FDA changes, Regenxbio will submit Duchenne gene therapy for approval
https://www.statnews.com/2026/06/24/regenxbio-duchenne-gene-therapy-fda-submission/REGENXBIO to resubmit application for Hunter gene therapy after FDA’s most recent pivot - BioSpace
https://www.biospace.com/fda/regenxbio-to-resubmit-application-for-hunter-gene-therapy-after-fdas-most-recent-pivot